Appropriate mineralocorticoid receptor antagonism and salt restriction are essential for primary aldosteronism therapy

被引:1
|
作者
Sawami, Kosuke [1 ,2 ]
Tanaka, Atsushi [2 ]
Node, Koichi [2 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan
[2] Saga Univ, Dept Cardiovasc Med, Saga, Japan
关键词
Primary aldosteronism; Mineralocorticoid receptor antagonism; Salt restriction;
D O I
10.1038/s41440-022-01155-0
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
引用
收藏
页码:794 / 796
页数:3
相关论文
共 50 条
  • [41] Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity
    Okamura, Keisuke
    Matsushima, Masatoshi
    Takamiya, Yosuke
    Okuda, Tetsu
    Sako, Hideto
    Udo, Akihiro
    Taniguchi, Kenichiro
    Morisaki, Shogo
    Imamura, Ichiro
    Urata, Hidenori
    Miura, Shin-ichiro
    JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA, 2024, 16 (10): : 509 - 517
  • [42] Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism
    Yoshida, Yuichi
    Shibata, Hirotaka
    HYPERTENSION RESEARCH, 2025, 48 (02) : 854 - 861
  • [43] FEASIBILITY OF SUBTYPING OF PRIMARY ALDOSTERONISM BY ADRENAL VEIN SAMPLING DURING MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT
    Pintus, Giovanni
    Teresa, Seccia Maria
    Domenico, Bagordo
    Brasilina, Caroccia
    Giulio, Ceolotto
    Livia, Lenzini
    Giacomo, Rossitto
    Paolo, Rossi Gian
    JOURNAL OF HYPERTENSION, 2024, 42
  • [44] Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
    Shi, Luo
    Yuan, Fang
    Wang, Xuefang
    Wang, Ri
    Liu, Kun
    Tian, Yanming
    Guo, Zan
    Zhang, Xiangjian
    Wang, Sheng
    FRONTIERS IN PHYSIOLOGY, 2019, 10
  • [45] The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression - Lessons from primary aldosteronism
    Murck, Harald
    Schlageter, Lena
    Schneider, Anna
    Adolf, Christian
    Heinrich, Daniel
    Quinkler, Marcus
    Beuschlein, Felix
    Reincke, Martin
    Kuenzel, Heike
    JOURNAL OF PSYCHIATRIC RESEARCH, 2020, 130 : 82 - 88
  • [46] Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism
    Hundemer, Gregory L.
    Curhan, Gary C.
    Yozamp, Nicholas
    Wang, Molin
    Vaidya, Anand
    JAMA CARDIOLOGY, 2018, 3 (08) : 768 - 774
  • [47] Antihypertensive effects and changes in extracellular water content by mineralocorticoid receptor antagonists in patients with primary aldosteronism
    Matsuda, Naoki
    Yoshida, Yuichi
    Inobe, Naruto
    Yoshimura, Mio
    Iwamoto, Miyuki
    Nagai, Satoshi
    Sada, Kentaro
    Noguchi, Takaaki
    Yonezu, Chiaki
    Imaishi, Nao
    Morita, Machiko
    Mori, Yumi
    Miyamoto, Shotaro
    Ozeki, Yoshinori
    Okamoto, Mitsuhiro
    Gotoh, Koro
    Masaki, Takayuki
    Shibata, Hirotaka
    HYPERTENSION RESEARCH, 2025, 48 (02) : 553 - 562
  • [48] OBSTRUCTIVE SLEEP APNOEA IS COMMON IN PATIENTS WITH PRIMARY ALDOSTERONISM AND IMPROVES WITH ADRENALECTOMY OR MINERALOCORTICOID RECEPTOR ANTAGONISTS
    Wolley, M. J.
    Cowley, D.
    Ahmed, A.
    Gordon, R. D.
    Stowasser, M.
    HYPERTENSION, 2016, 67 (05) : E20 - E20
  • [49] Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan
    Wu, Vin-Cent
    Hu, Ya-Hui
    Wu, Che-Hsiung
    Kao, Chih-Chin
    Wang, Cheng-Yi
    Yang, Wei-Shen
    Lee, Hsiu-Hao
    Chang, Yuan-Shian
    Lin, Yen-Hung
    Wang, Shuo-Meng
    Chen, Likwang
    Wu, Kwan-Dun
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2014, 67 (10) : 1139 - 1149
  • [50] Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy
    Kolkhof, Peter
    Joseph, Amer
    Kintscher, Ulrich
    PHARMACOLOGICAL RESEARCH, 2021, 172